| abstract |
The disclosure relates to an adeno-associated virus (AAV) vector comprising a capsid comprising proteins VP1, VP2, VP3, and VP1.5 protein, of AAV1, AAV6, AAV8, or AAV9, further comprising a minigene comprising AAV inverted terminal repeats and a heterologous nucleic acid sequence operably linked to regulatory sequences. The disclosure also relates to a pharmaceutical composition comprising said AAV vector and the use of said AAV vector. The present disclosure can be used in the gene therapy field to treat genetic and infectious diseases. |